News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
738,036 Results
Type
Article (43576)
Company Profile (322)
Press Release (694128)
Multimedia
Podcasts (113)
Webinars (19)
Section
Business (210886)
Career Advice (2104)
Deals (36731)
Drug Delivery (118)
Drug Development (83352)
Employer Resources (177)
FDA (16784)
Job Trends (15487)
News (357125)
Policy (34100)
Tag
Academia (2602)
Accelerated approval (25)
Adcomms (25)
Allergies (129)
Alliances (51583)
ALS (162)
Alzheimer's disease (1645)
Antibody-drug conjugate (ADC) (282)
Approvals (16977)
Artificial intelligence (478)
Autoimmune disease (118)
Automation (33)
Bankruptcy (372)
Best Places to Work (11773)
BIOSECURE Act (21)
Biosimilars (180)
Biotechnology (190)
Bladder cancer (147)
Brain cancer (56)
Breast cancer (599)
Cancer (4488)
Cardiovascular disease (377)
Career advice (1780)
Career pathing (35)
CAR-T (266)
CDC (47)
Celiac Disease (1)
Cell therapy (699)
Cervical cancer (35)
Clinical research (70636)
Collaboration (1523)
Company closure (4)
Compensation (1054)
Complete response letters (54)
COVID-19 (2768)
CRISPR (87)
C-suite (713)
Cystic fibrosis (141)
Data (5759)
Decentralized trials (2)
Denatured (36)
Depression (115)
Diabetes (467)
Diagnostics (6691)
Digital health (38)
Diversity (11)
Diversity, equity & inclusion (45)
Drug discovery (225)
Drug pricing (185)
Drug shortages (31)
Duchenne muscular dystrophy (214)
Earnings (91458)
Editorial (53)
Employer branding (22)
Employer resources (155)
Events (119536)
Executive appointments (963)
FDA (19579)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (7)
Frontotemporal dementia (20)
Funding (1350)
Gene editing (187)
Generative AI (40)
Gene therapy (561)
GLP-1 (965)
Government (4767)
Grass and pollen (7)
Guidances (377)
Healthcare (19043)
HIV (48)
Huntington's disease (40)
IgA nephropathy (77)
Immunology and inflammation (241)
Immuno-oncology (38)
Indications (77)
Infectious disease (3012)
Inflammatory bowel disease (184)
Inflation Reduction Act (13)
Influenza (103)
Intellectual property (216)
Interviews (326)
IPO (16900)
IRA (55)
Job creations (4068)
Job search strategy (1498)
Kidney cancer (15)
Labor market (79)
Layoffs (572)
Leadership (31)
Legal (8415)
Liver cancer (89)
Longevity (13)
Lung cancer (615)
Lymphoma (353)
Machine learning (38)
Management (60)
Manufacturing (701)
MASH (158)
Medical device (13776)
Medtech (13813)
Mergers & acquisitions (20796)
Metabolic disorders (1183)
Multiple sclerosis (143)
NASH (17)
Neurodegenerative disease (284)
Neuropsychiatric disorders (73)
Neuroscience (2760)
NextGen: Class of 2025 (6645)
Non-profit (4550)
Now hiring (61)
Obesity (551)
Opinion (274)
Ovarian cancer (150)
Pain (191)
Pancreatic cancer (197)
Parkinson's disease (256)
Partnered (32)
Patents (455)
Patient recruitment (408)
Peanut (57)
People (60560)
Pharmaceutical (91)
Pharmacy benefit managers (28)
Phase I (21918)
Phase II (31058)
Phase III (23294)
Pipeline (3901)
Policy (277)
Postmarket research (2655)
Preclinical (9352)
Press Release (68)
Prostate cancer (217)
Psychedelics (45)
Radiopharmaceuticals (271)
Rare diseases (748)
Real estate (6299)
Recruiting (72)
Regulatory (24862)
Reports (51)
Research institute (2423)
Resumes & cover letters (360)
Rett syndrome (23)
RNA editing (13)
RSV (73)
Schizophrenia (143)
Series A (226)
Series B (169)
Service/supplier (12)
Sickle cell disease (94)
Special edition (23)
Spinal muscular atrophy (156)
Sponsored (41)
Startups (3758)
State (2)
Stomach cancer (17)
Supply chain (99)
Tariffs (92)
The Weekly (75)
Vaccines (976)
Venture capital (77)
Weight loss (366)
Women's health (74)
Worklife (17)
Date
Today (94)
Last 7 days (528)
Last 30 days (2354)
Last 365 days (30677)
2025 (30358)
2024 (35774)
2023 (40631)
2022 (51799)
2021 (56330)
2020 (54793)
2019 (47398)
2018 (35771)
2017 (33138)
2016 (32663)
2015 (38615)
2014 (32516)
2013 (27630)
2012 (29729)
2011 (30487)
2010 (28497)
Location
Africa (800)
Alabama (77)
Alaska (7)
Arizona (297)
Arkansas (14)
Asia (41888)
Australia (6703)
California (10482)
Canada (3116)
China (1014)
Colorado (440)
Connecticut (447)
Delaware (314)
Europe (89774)
Florida (1553)
Georgia (332)
Hawaii (2)
Idaho (61)
Illinois (805)
India (57)
Indiana (502)
Iowa (20)
Japan (382)
Kansas (122)
Kentucky (36)
Louisiana (24)
Maine (70)
Maryland (1319)
Massachusetts (7602)
Michigan (305)
Minnesota (592)
Mississippi (5)
Missouri (121)
Montana (30)
Nebraska (26)
Nevada (113)
New Hampshire (73)
New Jersey (2826)
New Mexico (29)
New York (2797)
North Carolina (1383)
North Dakota (8)
Northern California (5027)
Ohio (309)
Oklahoma (21)
Oregon (43)
Pennsylvania (2156)
Puerto Rico (19)
Rhode Island (45)
South America (1168)
South Carolina (60)
South Dakota (1)
Southern California (4058)
Tennessee (163)
Texas (1621)
United States (37586)
Utah (311)
Vermont (1)
Virginia (254)
Washington D.C. (78)
Washington State (865)
West Virginia (4)
Wisconsin (95)
Wyoming (2)
738,036 Results for "biomarin pharmaceutical inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Mergers & acquisitions
BioMarin Pumps Up Revenue Goals With $4.8B Amicus Purchase
BioMarin Pharmaceutical has faced a rocky road, promising and then backing off revenue targets and cutting assets that have underperformed. But Amicus’ rare disease portfolio is already bringing in $600 million annually.
December 19, 2025
·
2 min read
·
Dan Samorodnitsky
Earnings
BioMarin Abandons Gene Therapy Roctavian, Cuts Revenue Guidance as Voxzogo Faces Competitors
BioMarin no longer expects to hit its $4 billion revenue target by 2027, citing various market factors such as impending competition for achondroplasia therapy Voxzogo and the divestment of the gene therapy Roctavian.
October 28, 2025
·
4 min read
·
Tristan Manalac
Rare Diseases
Ascendis Readies BioMarin Challenge in Achondroplasia While Others Search for Root Cause
Therapies from industry leaders BioMarin and Ascendis Pharma supply a key hormone that promotes bone growth. In order to move the field forward, challengers are looking to address the underlying cause of the rare, genetic disease.
October 13, 2025
·
7 min read
·
Tristan Manalac
Rare diseases
BioMarin Axes Pre-Clinical PKU Drug, Citing Underwhelming Immunogenicity
BMN 390 fell short of an immunogenicity threshold that BioMarin was looking for to support its further development. Employees working on the program have been redeployed within the company.
August 5, 2025
·
2 min read
·
Tristan Manalac
Press Releases
BioMarin Reports Third Quarter 2025 Results and Provides Corporate Update
October 28, 2025
·
25 min read
FDA
FDA Delays Decision on Ascendis’ Dwarfism Drug by Three Months
If approved, Ascendis’ TransCon CNP would become the second therapy for achondroplasia, challenging BioMarin’s Voxzogo.
December 1, 2025
·
1 min read
·
Tristan Manalac
Press Releases
BioMarin to Participate at the Jefferies Global Healthcare Conference on Tuesday, November 18, 2025, at 10:30 AM GMT in London, England
November 11, 2025
·
1 min read
Press Releases
BioMarin to Participate in Upcoming September 2025 Investor Conferences
August 28, 2025
·
1 min read
Press Releases
BioMarin to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Monday, October 27, 2025, at 4:30pm ET
October 22, 2025
·
1 min read
Opinion
Competition for Achondroplasia Treatments Heats Up Slowly
Achondroplasia, which affects around one in 20,000 babies, has just one approved treatment: BioMarin’s Voxzogo. However, new investigational treatments are vying to compete in the area.
January 27, 2025
·
4 min read
·
Jia Jie Chen
1 of 73,804
Next
